This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (74)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

The Use of Medications to Promote Sleep

JAMA. 1984;251(18):2410-2414.

Abstract
The past decade has provided new developments and methodologies in sleep research, clinical practices, neuropharmacology, and psychiatric diagnoses. A taxonomy of sleep disorders has been advanced, and there are two newly marketed hypnotic drugs that are rapidly eliminated, as well as others under development. Use of a sleep-promoting medication is a decision that physicians and patients alike frequently encounter.

A recent national survey found that one third of the population reported some degree of insomnia, and half of this group—17% of the population—considered the insomnia serious. Half of the group with "serious insomnia" reported a high level of emotional distress. Only 10% of the subjects reporting "severe" insomnia received prescribed sleep-promoting medications; 5% used over-the-counter compounds. Surveys of primary care practice indicate that the bulk of hypnotic drug therapy is directed to women and the elderly with medical or mental disorders and only a very small proportion with a primary diagnosis of insomnia.

Since insomnia occurs in different diagnostic contexts and under a variety of circumstances, it is often difficult for the physician to know whether, when, and how to select and use hypnotics and other sleep-promoting medications. Yet, with the more extensive pharmacologic and clinical information now available, more effective day-to-day clinical decision making is possible.

As an aid to clinicians, the National Institute of Mental Health and Office of Medical Applications of Research of the National Institutes of Health convened a Consensus Development Conference on Nov 15 through 17, 1983, to address these questions and develop principles to facilitate diagnosis and treatment. After a day and a half of presentation of data by experts, a Consensus Panel consisting of psychiatrists, psychopharmacologists, biomedical researchers, epidemiologists, primary care physicians, and public representatives considered the evidence and agreed on answers to the following questions:

1. Under what circumstances might a sleep-promoting medication be considered; in what types of sleep disturbances are sleep-promoting medications undesirable?
   
2. What are the pharmacologic factors to be considered in the selection of sleep-promoting medications?
   
3. What are the appropriate treatment strategies to be employed in using sleep-promoting medications on a short-term or long-term basis?
   
4. What are the principal cautions and risks associated with prescribing these drugs; what special considerations should be applied in regard to medical status, age, concurrent drug use, or other factors?
   
5. What research areas need further development?
   

Footnotes
From the Office of Medical Applications of Research, National Institutes of Health, Bethesda, Md.

Reprint requests to the Office of Medical Applications of Research, Bldg 1, Room 216, National Institutes of Health, Bethesda, MD 20205 (Michael J. Bernstein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Consequences of comorbid insomnia symptoms and sleep-related breathing disorder in elderly subjects.
Gooneratne et al.
Arch Intern Med 2006;166:1732-1738.
ABSTRACT | FULL TEXT  

Randomized Study on the Efficacy of Cognitive-Behavioral Therapy for Insomnia Secondary to Breast Cancer, Part I: Sleep and Psychological Effects
Savard et al.
JCO 2005;23:6083-6096.
ABSTRACT | FULL TEXT  

Diagnosis and Treatment of Chronic Insomnia: A Review
Benca
Psychiatr. Serv. 2005;56:332-343.
ABSTRACT | FULL TEXT  

Randomized Clinical Trial of Supervised Tapering and Cognitive Behavior Therapy to Facilitate Benzodiazepine Discontinuation in Older Adults With Chronic Insomnia
Morin et al.
Am. J. Psychiatry 2004;161:332-342.
ABSTRACT | FULL TEXT  

Maintenance Treatment of Insomnia: What Can We Learn From the Depression Literature?
Jindal et al.
Am. J. Psychiatry 2004;161:19-24.
ABSTRACT | FULL TEXT  

Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial
Baillargeon et al.
CMAJ 2003;169:1015-1020.
ABSTRACT | FULL TEXT  

Hypnotic Dependent Insomnia in an Older Adult with Addiction-Prone Personality
Cooper et al.
Clinical Case Studies 2003;2:247-258.
ABSTRACT  

Secondary Otalgia in an Adult Population
Kuttila et al.
Arch Otolaryngol Head Neck Surg 2001;127:401-405.
ABSTRACT | FULL TEXT  

The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach
Holbrook et al.
CMAJ 2000;162:216-210.
ABSTRACT | FULL TEXT  

Facilitation of Benzodiazepine Discontinuation by Melatonin: A New Clinical Approach
Garfinkel et al.
Arch Intern Med 1999;159:2456-2460.
ABSTRACT | FULL TEXT  

Relaxation to Assist Sleep Medication Withdrawal
Lichstein et al.
Behav Modif 1999;23:379-402.
ABSTRACT  

Treating Insomnia in Older Adults: Taking a Long-term View
Reynolds III et al.
JAMA 1999;281:1034-1035.
FULL TEXT  

The safety and tolerability of zolpidem -- an update
Darcourt et al.
J Psychopharmacol 1999;13:81-93.
ABSTRACT  

A Comparison of the Efficacy of Stimulus Control for Medicated and Nonmedicated Insomniacs
Riedel et al.
Behav Modif 1998;22:3-28.
ABSTRACT  

Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy
Nowell et al.
JAMA 1997;278:2170-2177.
ABSTRACT  

The Natural History of Insomnia and Its Relationship to Respiratory Symptoms
Dodge et al.
Arch Intern Med 1995;155:1797-1800.
ABSTRACT  

Adverse Behavioral Reactions Attributed to Triazolam in the Food and Drug Administration's Spontaneous Reporting System
Wysowski and Barash
Arch Intern Med 1991;151:2003-2008.
ABSTRACT  

Outpatient Use of Prescription Sedative-Hypnotic Drugs in the United States, 1970 Through 1989
Wysowski and Baum
Arch Intern Med 1991;151:1779-1783.
ABSTRACT  

Effects of Patient Age and Physician Training on Choice and Dose of Benzodiazepine Hypnotic Drugs
Shorr and Bauwens
Arch Intern Med 1990;150:293-295.
ABSTRACT  

Sleep Disorders
Wincor
Journal of Pharmacy Practice 1990;3:221-232.
ABSTRACT  

The Implications of Sleep Disturbance Epidemiology
Reynolds
JAMA 1989;262:1514-1514.
ABSTRACT  

Drug Prescribing for the Elderly
Everitt and Avorn
Arch Intern Med 1986;146:2393-2396.
ABSTRACT  

Insomnia and Its Treatment: Prevalence and Correlates
Mellinger et al.
Arch Gen Psychiatry 1985;42:225-232.
ABSTRACT  

Flurazepam and Other Benzodiazepines
FINUCANE
ANN INTERN MED 1984;101:403-404.
ABSTRACT